Quarterly report pursuant to Section 13 or 15(d)

Stock-Based Compensation, Restricted Stock and Stock Options (Tables)

v3.23.1
Stock-Based Compensation, Restricted Stock and Stock Options (Tables)
3 Months Ended 12 Months Ended
Mar. 31, 2023
Dec. 31, 2022
Stock-Based Compensation, Restricted Stock and Stock Options [Abstract]    
Schedule of stock-based compensation
    Three months ended
March 31,
 
    2023     2022  
    (Unaudited)     (Unaudited)  
Research and development expenses   $ 59     $ 55  
Selling, general and administrative expenses     122       1,028  
Total stock-based compensation   $ 181     $ 1,083  

 

 
Schedule of activity under the 2016 and 2020 plans
    Shares
Underlying
Options
    Weighted
Average
Exercise
Price
    Weighted Average
Remaining
Contractual
Term (Years)
    Aggregate
Intrinsic
Value
 
Outstanding at December 31, 2022     9,513,624     $ 2.64       6.5     $ 26,188  
Forfeited     (90,138 )   $ 3.29      
-
         
Outstanding at March 31, 2023     9,423,486     $ 2.63       6.3     $
-
 
                                 
Exercisable at March 31, 2023     8,521,662     $ 2.80       6.0     $
-
 

 

 
Schedule of restricted stock activity
    Number of
Shares
    Weighted Average
Grant-Date
Fair Value
 
Unvested at January 1, 2023     628,780     $ 1.37  
Vested     (130,867 )   $ 1.55  
Unvested at March 31, 2023     497,913     $ 1.32  

 

 
Schedule of warrant (excluding penny warrants) activity  
    Shares
Underlying
Warrants
    Weighted
Average
Exercise
Price
    Weighted
Average
Remaining
Contractual
Term (Years)
    Aggregate
Intrinsic
Value
 
Outstanding at December 31, 2022     27,661,181     $ 0.75       4.5     $
      -
 
Issued     14,764,258     $ 0.32       4.7      
 
 
Exercised     (6,405,844 )   $ 0.32      
-
     
 
 
Outstanding at March 31, 2023     36,019,595     $ 0.65       4.4     $
-